novel protodioscin-enriched fenugreek seed extract (Trigonella foenum-graecum, family Fabaceae) improves free testosterone level and sperm profile in healthy volunteers. Functional Foods in Health and Disease 2017; 7(4); 235-245 ABSTRACT Background: A novel, patent-pending 20% protodioscin-enriched extract has been developed in our laboratories from fenugreek seeds (Furosap ® ). We assessed the efficacy of Furosap ® in 50 male volunteers (age: 35-65 years) on free and total increased testosterone levels, sperm profile, mental alertness, cardiovascular health, mood, libido, and quality of life.
INTRODUCTION
Fenugreek plant and seeds are rich in soluble fibers, and extensively used in Ayurvedic, Chinese and Unani medicines for anti-inflammatory, anti-diabetic, antiseptic, aphrodisiac, women's health, and diverse health benefits for centuries [1] [2] [3] [4] [5] [6] [7] [8] [9] . Fenugreek leaves, twigs, roots, sprouts, microgreens and yellow to amber colored, cuboid-shaped seeds are extensively used in versatile culinary purposes including spices, salads, soups, brewed into a tea, baked into a bread, and pickles in the Asian countries [1] [2] [3] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The fenugreek seeds are often roasted to optimize bitterness and flavor [3, 6, 9] . Literature reveals that fenugreek contains approximately 28% mucilage, 5% stronger-smelling, bitter fixed oil, rich in phosphates, lecithin and nucleoalbumin, considerable amounts of readily absorbable iron in an organic form, in addition to trigonelline, trimethylamine, choline, biotin, inositol, vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B9, vitamin B12, and vitamin D, diosgenin, diosgenin-β−D-glucoside, neurin, betaine, vitexin, vitexin-7-glucoside, yamogenin, vicenin, saponaretin, and isoorientin [4] [5] [6] [7] [8] 12] .
Fenugreek and its seeds have exhibited versatile health benefits including antioxidant, antiinflammatory benefits, anti-diabetic, hypercholesterolemia, polycystic ovary syndrome, gastric ulcer and hyperthyroidism, and exercise [4] [5] [6] [7] [8] [9] [10] [11] [12] . The dose-dependent efficacy of fenugreek seed extract (0, 150 or 300 mg/kg body weight) was investigated over a period of 4 weeks in male mice on endurance capacity in a swimming model [13] . The swimming endurance was significantly increased at 300 mg/kg body weight dose. The authors reported that the utilization of fatty acids was also significantly increased as an energy source at this dose [13] . also assessed the efficacy of fenugreek seed (0, 0.8 or 1.6 g/kg body weight) extract in combination with swimming exercise compared to glibenclamide in type 2 diabetic male rats [14, 15] . It was concluded that fenugreek seed consumption, along with swimming exercise, induced a therapeutic efficacy on the improvement of anti-diabetic profiles including plasma insulin, HOMA-IR, plasma leptin, and adiponectin [14, 15] .
In a placebo-controlled, double blind study in 49 resistance-trained male volunteers, Poole et al. (2010) assessed the effect of fenugreek supplementation (500 mg/day) on strength, body composition, muscle endurance, power output, and hormonal profiles over a period of 8 weeks. The study demonstrated that fenugreek can significantly increase upper and lower-body strength, reduce body fat and improve overall body composition [16] .
This study assessed the efficacy of a novel, patented fenugreek (Trigonella foenum-graecum) seed extract enriched in 20% protodioscin (Furosap ® , US Patents# US 8,217,165 B2; US 8,754, 205 B2) [17, 18] to boost free testosterone levels, sperm profile and morphology, sexual health, sexual arousal, mood and mental alertness, and broad spectrum safety parameters in 50 male volunteers (Age: 35-65 years) over a period of 12 weeks. pulse/minute). Inclusion criteria: male subjects (age 35-65 years) diagnosed with symptomatic hypogonadism, understanding the risks/benefits of the protocol, and agreeing to the written in addition to the audio-visual informed consent. Exclusion criteria: uncooperative subjects, receiving any other testosterone boosters for the last 2 months, suffering from coronary artery disease and allied complications, history of malignancy, coagulopathies (clotting and bleeding), psychiatric disorders or hypersensitivity to Furosap®, high alcohol intake (>2 drinks per day), abnormal hepatic or renal functions (ALT or AST > 2 times the upper limit of normal; creatinine> 125 µmol/L), impaired liver function >2.5 times the upper limit of normal, and any particular medical condition where the investigator believes participation in this study could be detrimental to the overall well-being of subjects. Enrolled subjects were given Furosap® (1 capsule of 500 mg each/day after breakfast) over a period of 12 consecutive weeks. Furosap® was given to the subjects by the site staff and records were maintained in the IP accountability log. All data were maintained separately with the date/signature of the principal investigator & study coordinators. Any concomitant prescription medications taken during study participation were recorded on the case report forms (CRFs). All medications including prescription medications, over-the-counter medications (OTC) and non-prescription medications taken during the clinical study were meticulously recorded and routinely examined by the principal investigator & study coordinators.
MATERIALS AND METHODS

Methods
The efficacy of Furosap® (500 mg/day) was assessed on 50 male volunteers, with clinical evaluations being conducted at the baseline, at the end of 4 and 8-weeks, and at the end of 12 weeks. A preliminary in-house study was conducted to determine this effective dose of Furosap®. BMI (kg/m 2 ), free testosterone (pg/ml), total testosterone (ng/dl), dehydroepiandrosterone sufate (DHEA-S), fasting blood sugar (FBS), fasting lipid profile (total cholesterol, LDL, HDL, triglycerides, VLDL), liver function test (AST, ALT, ALP), semen examination (sperm count, sperm motility, sperm morphology, and hemogram were extensively assessed at the baseline and at the end of 12 weeks respectively. However, BMI, fasting lipid profile and semen examination were assessed at the end of 4 and 8-weeks respectively. Sexual health and sexual arousal were assessed at 4, 8, and 12-weeks of Furosap® treatment. Free testosterone was measured using a Dia Sources' ELISA kit (catalog#CAN-FTE-260) purchased from Krishgen Biosystems, Mumbai, India, and total testosterone was assessed using an automated bidirectionally interfaced Chemiluminescent Immunoassay (CLIA) from Siemens Health Care Pvt Ltd, Mumbai, India. Dehydroepiandrosterone sulfate (DHEA-S) was assessed using the Cobas Electrochemiluminescence Immunoassay (ECLIA) (catalog# 03000087122) kit purchased from Roche Diagnostics India Pvt Ltd, Mumbai, India. Hemoglobin level was evaluated using a Sysmex fully automated bidirectional analyzer (SYSMEX XN-1000) purchased from Transasia Bio Medicals Ltd, Mumbai, India, and fasting blood glucose (FBS) levels were assessed using photometry technology (Agappe Diagnostics Ltd, Mumbai, India). Aspartate Aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT), blood urea nitrogen (BUN), cholesterol, triglycerides, high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), very low density lipoprotein (VLDL), total leukocytes count (TLC), neutrophils, lymphocytes, monocytes, eosinophils and basophils in Central Processing Lab (CPL, a division of Thyrocare, Mumbai, India) and Regional Processing Lab (RPL, a division of Thyrocare, Mumbai, India). Sperm count, sperm motility and abnormal sperm morphology were assessed in Nigam Pathology (Lucknow, India).
Adverse Events
Adverse event reporting was strictly enforced.
Statistical Analysis
Data is expressed as mean ± SD (standard deviation) or SEM (standard error mean). All parametric and non-parametric assessments were conducted. Wilcoxon signed-rank test, a nonparametric test equivalent to the dependent t-test, was used for assessing mental alertness, mood, reflex erection, and overall performance.
RESULTS
Furosap®(FS)-induced effect on free testosterone and total testosterone
Male volunteers were treated with FS over a period of 12 consecutive weeks. Free testosterone and total testosterone levels were assessed at the baseline and at the end of 12 weeks of treatment (Figure 1) . Furosap®-induced a significant increase in free testosterone level by approximately 1.47-fold (p value = 0.0004**), while the total testosterone level was increased marginally only by 1.08-fold (p-value = 0.164ns). Non-significant reduction in abnormal sperm morphology (%) was recorded at 4-weeks posttreatment. However, abnormal sperm morphology (%) was significantly reduced both at 8 and 12-weeks post-treatment respectively (Table 1) . 
Effect of Furosap® on dehydroepiandrosterone sulfate (DHEA-S), fasting blood sugar (FBS) and total leukocyte count (TLC)
DHEA-S, FBS and TLC levels were measured at the baseline and at 12 weeks of treatment. No significant changes were observed ( Figure 2 ).
Figure 2. Furosap-induced effect on dehydroeplandrosterone (DHEA-S), fasting blood sugar (FBS) and total leukocyte count (TLC) at baseline end of 12 weeks of treatment
The time-dependent effect of Furosap on mental alertness, mood alleviation, reflex erection and overall performance at the baseline, week 4, week 8, and week 12 of treatment Mental alertness, mood alleviation, reflex erection, and overall performance were assessed at the baseline, week 4, week 8, and week 12 of treatment (data not shown). Wilcoxon signed-rank test, a nonparametric test equivalent to the dependent t-test, were used to assess the statistical significance. Significant improvements were observed for all these parameters at all time points. (Table 2) . Average frequency exhibited a time-dependent escalation, which was approximately doubled at the end of 12 weeks (p<0.000*) ( Table 2 ). On visit 1 (after 4-weeks of completion), 65.3% subjects showed significant improvements, while 95.9% subjects showed significant improvements after 8-weeks of treatment (visit 2). On visit 3 (after 12-weeks of completion), a total of 98% population exhibited significant improvement in sexual arousal. 
DISCUSSION
A broad spectrum of studies has demonstrated that fenugreek (Trigonella foenum-graecum) has exhibited a significant number of health benefits. Fenugreek attenuated body weight gain, obesity and metabolic syndrome related complications, improved insulin sensitivity, anti-diabetic efficacy, muscle building, physical and sexual health, polycystic ovary syndrome, women reproductive disorders, and several others [2, 4, [6] [7] [8] [9] [10] [11] [12] . From ancient times, Ayurvedic, Unani, and Chinese medicines have repeated demonstrated the multiple medicinal and therapeutic benefits of fenugreek leaves, twigs, and seeds in a broad spectrum of human diseases and ailments including diabetes, obesity, women reproductive disorders, muscle building, and wrestling [4] [5] [6] [7] [19] [20] [21] [22] [23] . Fenugreek seeds have demonstrated to contain selected furostanolic saponins, protodioscin, B vitamins, vitamin D, 4-hydroxyisoleucine, diosgenin, diosgenin-β−D-glucoside, and others. A gas chromatography-mass spectrometry analysis of fenugreek extract revealed the presence of cedrene, eugenol, gingerol, vanillin, and zingerone [24] . An in vitro study by Tomcik et al. [25] demonstrated that fenugreek seeds in combination with insulin significantly modulated creatine content via a mechanism independent of the activity of a sodium and chloride-dependent creatine transporter, SLC6A8 [25] . In the recent past, another independent study by Hamden et al. [26] demonstrated that following the administration of fenugreek seeds to diabetic rats, there was significant decrease of sperm shape abnormality and improvement of the sperm count. Furthermore, the potential protective efficacy of fenugreek seed extract was observed on reproductive systems, as demonstrated by histological studies on testis and epididymis [26] . Aswar et al. [27] assessed the efficacy of fenugreek seed extract (10 mg/kg s.c. bi-weekly or 10 and 35 mg/kg body weight orally on immature castrated male Wistar rats. Some anabolic activity was observed in these animals without androgenic activity [27] . Fenugreek seed extract also displayed selective cytotoxic activity against T-cell and B-cell lymphoma in vitro. In T-cell lymphoma, the anticancer effect was mediated through induction of apoptosis [28] . Interestingly, protodioscin-enriched fenugreek seed extract exhibited strong growth-inhibitory activity against HL-60 human leukemia cells. Morphological, flow cytometric and molecular analyses revealed induction of apoptosis of tumor cells [11] . Verma et al. [29] reported in vitro anticancer effect of fenugreek whole plant extract against A-549 human lung cancer cells. Treatment of A-549 cells with fenugreek extract diosgenin and pure diosgenin inhibited the growth of cancer cells and caused down-regulation of hTERT expression, indicating abrogation of telomerase activity [30, 31] . This may contribute significantly in the application of Furasap ® in sports nutrition. Our studies have demonstrated the significant efficacy of Furosap ® in significantly improving sperm morphology and down-regulating abnormal sperm morphology. Multiple human studies were conducted in the recent past demonstrating the efficacy of fenugreek seeds in boosting both free and total testosterone levels, thereby improving sexual and physical health. Testosterone has also been demonstrated to attenuate lean body mass and stronger bones. A clinical investigation in 49 resistance-trained male subjects demonstrated that fenugreek seed extract (500 mg/day) had a significant impact on both upper and lower-body strength in addition to body composition in a double-blind placebo-controlled study [16] . Three independent studies demonstrated the clinical efficacy fenugreek extract in boosting testosterone levels [32] [33] [34] . The authors indicated that a positive effect was observed on the physiological aspects of libido, muscle strength, and energy. The second study was conducted in 80 healthy menstruating women who reported low sexual drive (age: 20 to 49 years; dose: 600 mg/day), which demonstrated that fenugreek seed extract is beneficial for boosting sexual arousal and desire in women. The third randomized, double-blind, placebo-controlled study was conducted in 120 men (age: 43-70 years; daily dose of fenugreek extract: 600 mg) over a period of 12 weeks. Both free and total testosterone levels and sexual function increased significantly after 12 weeks of treatment [32] [33] [34] .
This investigation exhibited that Furosap®, enriched in 20% protodioscin, is instrumental in significantly enhancing free testosterone level, sperm count, sperm motility, mental alertness, mood alleviation, reflex erection, sexual health, sexual arousal, and overall performance in healthy male volunteers.
CONCLUSION
This clinical study demonstrates that Furosap®, a novel, 20% protodioscin-enriched extract from Trigonella foenum-graecum seeds significantly increased free testosterone levels by 1.47-fold (p value = 0.000**) following treatment for a period of 12 weeks, while the total testosterone level was marginally increased by 1.08-fold. Statistically significant increases were observed in sperm count and sperm motility at 4, 8, and 12-weeks of Furosap® treatment, while a statistically significant decrease in abnormal sperm morphology was observed. Sexual health, sexual arousal, and overall performance were significantly increased. Mental alertness, mood alleviation, reflex erection, and overall performance were significantly alleviated at week-4, week-8, and week-12 of treatment. Cardiovascular health was significantly improved. Furthermore, the broad spectrum lipid profile and blood chemistry analyses data demonstrated the safety of Furosap®.
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